FDA approves revumenib, a menin inhibitor, for relapsed or refractory acute leukemia with a KMT2A translocation
Big news from Dana-Farber Cancer Institute regarding the FDA approval of revumenib for the treatment of relapsed acute leukemia! Gabrielle’s Angel Foundation funded Scott Armstrong, MD, PhD back in 2007 during the preliminary research of this project. These early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the development and testing of agents that inhibit menin, to work on preventing resistance to such agents directly led to the eventual development of revumenib and subsequent preclinical and clinical trials. We are proud to have supported Dr. Armstrong in this critical work!
